Anthropic has acquired Coefficient Bio, a stealth biotech AI startup founded barely eight months ago, in an all-stock deal worth just over $400 million. The acquisition brings a team of fewer than 10 people, nearly all former Genentech computational biology researchers, into Anthropic’s healthcare and life sciences division, and it signals something larger than a talent grab: the maker of Claude is staking real capital on the idea that general-purpose AI can accelerate drug discovery.
The deal, first reported by The Information on Thursday, values a company that had no publicly known product, no disclosed revenue, and no conventional traction metrics. What it did have was a founding team with rare credentials. Samuel Stanton and Nathan C. Frey, Coefficient Bio’s co-founders, both came from Prescient Design, Genentech’s computational drug discovery unit, where Frey led a multidisciplinary group working on biological foundation models and novel machine learning approaches to biomolecule design. Frey’s publication record spans more than 20 papers in journals including Science Advances and Nature Machine Intelligence, and he won an ICLR Outstanding Paper Award in 2024 for work on generative modelling for drug candidate discovery.
The startup’s stated ambition was nothing modest: artificial superintelligence for science. In practice, Coefficient Bio had built a platform enabling AI to draft drug research and development plans, manage clinical regulatory strategies, and identify new drug candidates. It was, by all accounts, a research-heavy operation that never left stealth mode.
Dimension, the New York-based venture firm founded in 2023 by former Lux Capital and Obvious Ventures partners Adam Goulburn, Zavain Dar, and Nan Li, held roughly half the company. The firm, which focuses on companies at the intersection of technology and life sciences, is now reporting a 38,513 per cent internal rate of return on the investment, a figure that says less about Coefficient Bio’s commercial viability than about the speed at which AI valuations are repricing early-stage science bets. Against Anthropic’s $380 billion post-money valuation, set in its $30 billion Series G round in February, the acquisition represents roughly 0.1 per cent dilution.
The 💜 of EU tech
The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!
The Coefficient Bio team will join Anthropic’s Health Care Life Sciences group, led by Eric Kauderer-Abrams, who was hired in 2025 with an explicit mandate to make Claude the dominant AI model in biology. “We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that that happens today with coding,” Kauderer-Abrams told CNBC when Anthropic launched Claude for Life Sciences in October 2025. That platform, which integrates with tools including Benchling, PubMed, and 10x Genomics, was designed to assist researchers across the entire drug discovery pipeline, from literature review and hypothesis generation to data analysis and regulatory submissions.
The acquisition deepens that push considerably. Where Claude for Life Sciences offered a generalised research assistant, Coefficient Bio’s team brings the kind of domain-specific expertise, particularly in protein design and biomolecule modelling, that could help Anthropic build specialised tools for pharmaceutical companies willing to pay enterprise prices for AI that understands their workflows at a molecular level.
Anthropic is not entering a vacuum. Google DeepMind spun off Isomorphic Labs to pursue AI-designed drug candidates now entering clinical trials, and Nvidia announced a five-year, $1 billion partnership with Eli Lilly in January to build an AI co-innovation lab for accelerated drug discovery. OpenAI, meanwhile, has been working with Moderna to speed the development of personalised cancer vaccines. The competitive logic is straightforward: whichever foundation model becomes embedded in biopharma R&D workflows will capture an enormous and recurring revenue stream in a market where a single approved drug can generate billions.
The venture capital appetite for AI-biology crossovers is reflecting this calculus. Breakout Ventures closed a $114 million fund in March explicitly targeting early-stage biotechs that treat AI and biology as inseparable. Dimension itself is reportedly raising a $700 million third fund to double down on the same thesis. The investor conviction is that the agentic AI wave will hit life sciences as forcefully as it has hit software engineering, and the acqui-hire economics of deals like Coefficient Bio suggest the large model builders agree.
For Anthropic, the strategic arithmetic is clear enough. The company’s run-rate revenue has reached $14 billion, growing more than tenfold annually for three consecutive years, and the customer base spending over $100,000 a year on Claude has grown sevenfold. But that growth is overwhelmingly concentrated in coding, enterprise search, and general productivity. Healthcare and life sciences represent a vast adjacent market where Anthropic has laid the groundwork with Claude for Life Sciences but has not yet achieved the kind of deep integration that generates sticky, high-margin revenue.
Paying $400 million in stock for a pre-revenue team of fewer than 10 people will, understandably, invite scepticism. The price looks less like a valuation of what Coefficient Bio had built and more like a statement about what Anthropic believes it can build with the right researchers on the payroll. Whether that bet pays off depends on something the current frenzy of AI startup valuations has not yet been forced to answer: whether frontier AI models can generate genuine scientific breakthroughs, or whether they will remain very expensive literature review assistants that happen to speak the language of molecular biology.
